Plasma levels of natriuretic peptides and development of chronic kidney disease.

Noriyuki Ogawa,Johji Kato,Hiroshi Komura,Kazuo Kitamura,Kenji Kuwasako

doi:10.1186/s12882-015-0163-9

Noriyuki Ogawa, Johji Kato + Show 3 more

Open Access

https://doi.org/10.1186/s12882-015-0163-9

Copy DOI

Abstract

BackgroundPlasma levels of atrial and brain natriuretic peptides (ANP and BNP) are increased in patients with chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the plasma level of ANP or BNP and the future development of CKD is unclear.MethodsWe measured the plasma ANP and BNP levels of 294 local residents without CKD in a Japanese community (56.5 ± 10.4 years, mean ± S.D.), who were followed up for the development of CKD over the next 7 years.ResultsSixty-three residents developed CKD during the follow-up period, and the baseline level of plasma ANP of these residents was significantly higher than in those without CKD development. Kaplan-Meier analysis showed that the residents with higher ANP than the median value developed CKD more frequently than those with lower ANP. The association between plasma ANP level and CKD development was found to be independent of baseline estimated glomerular filtration rate by a Cox proportional hazards model, while this association became insignificant when adjusted by age; plasma ANP was significantly correlated with age. Compared with ANP, the relationship between plasma BNP and CKD development was unclear in these analyses.ConclusionsAge-related elevation of plasma ANP levels preceded the development of CKD in the general population of Japan, raising a possibility for ANP being involved in the development of CKD.

Highlights

Plasma levels of atrial and brain natriuretic peptides (ANP and Brain natriuretic peptide (BNP)) are increased in patients with chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the plasma level of Atrial natriuretic peptide (ANP) or BNP and the future development of CKD is unclear
We examined whether the elevation of ANP or BNP levels in plasma is seen prior to the development of CKD by following up local residents without CKD for 7 years
We excluded those with medical history, symptoms or signs indicative of any heart disease, or with overt cardiovascular diseases, because plasma levels of ANP and BNP are elevated in patients with heart failure

Summary

Introduction

Plasma levels of atrial and brain natriuretic peptides (ANP and BNP) are increased in patients with chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the plasma level of ANP or BNP and the future development of CKD is unclear. A number of functional analysis studies have been performed, revealing that ANP and BNP have natriuretic or vasodilatory effects and direct cardiovascular protective actions, such as the inhibition of cardiac fibrosis and the suppression of vascular smooth muscle cell proliferation [3,4,5,6]. Their protective roles on the kidneys have . We examined whether the elevation of ANP or BNP levels in plasma is seen prior to the development of CKD by following up local residents without CKD for 7 years

Methods

Results

Discussion

Conclusion